KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Gross Profit (2009 - 2026)

Bristol Myers Squibb (BMY) reported Gross Profit of $8.1 billion for Q1 2026, down 1.22% year-over-year from $8.2 billion in Q1 2025, and down 4.01% on a QoQ basis from $8.4 billion in Q4 2025.

Bristol Myers Squibb (BMY) has 18 years of Gross Profit data on file, last reported at $8.1 billion in Q1 2026.

  • Quarterly Gross Profit fell 1.22% year-over-year to $8.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.2 billion (up 1.76% YoY) and the FY2025 annual result came in at $34.3 billion, changed 0.22% from the prior year.
  • Gross Profit declined to $8.1 billion in Q1 2026 per BMY's latest filing, from $8.4 billion in the prior quarter.
  • Across five years, Gross Profit topped out at $9.2 billion in Q1 2022 and bottomed at $7.5 billion in Q4 2024.
  • The 5-year median for Gross Profit is $8.8 billion (2025), against an average of $8.6 billion.
  • The widest annual swing landed in 2024, when Gross Profit dropped 13.77%; it then grew 11.62% in 2025.
  • Tracing BMY's Gross Profit over 5 years: stood at $8.8 billion in 2022, then slipped by 0.92% to $8.7 billion in 2023, then retreated by 13.77% to $7.5 billion in 2024, then grew by 11.62% to $8.4 billion in 2025, then decreased by 4.01% to $8.1 billion in 2026.
  • Per Business Quant, the three latest BMY Gross Profit figures stand at $8.1 billion (Q1 2026), $8.4 billion (Q4 2025), and $8.8 billion (Q3 2025).